Zoetis Inc. $ZTS Shares Bought by Laurel Wealth Advisors LLC

Laurel Wealth Advisors LLC grew its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 15,495.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 62,225 shares of the company’s stock after purchasing an additional 61,826 shares during the period. Laurel Wealth Advisors LLC’s holdings in Zoetis were worth $9,704,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Brighton Jones LLC boosted its stake in shares of Zoetis by 180.4% during the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after acquiring an additional 2,978 shares in the last quarter. LPL Financial LLC boosted its position in shares of Zoetis by 10.2% in the 1st quarter. LPL Financial LLC now owns 437,304 shares of the company’s stock valued at $71,640,000 after purchasing an additional 40,453 shares during the period. Foundations Investment Advisors LLC increased its stake in Zoetis by 10.6% in the 1st quarter. Foundations Investment Advisors LLC now owns 1,762 shares of the company’s stock worth $290,000 after purchasing an additional 169 shares in the last quarter. N.E.W. Advisory Services LLC acquired a new stake in Zoetis during the 1st quarter worth about $164,000. Finally, Geneos Wealth Management Inc. lifted its stake in Zoetis by 88.9% during the first quarter. Geneos Wealth Management Inc. now owns 27,778 shares of the company’s stock valued at $4,574,000 after buying an additional 13,073 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ZTS has been the topic of several analyst reports. UBS Group dropped their target price on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 5th. JPMorgan Chase & Co. lowered their price objective on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. KeyCorp assumed coverage on Zoetis in a report on Thursday, November 20th. They set a “sector weight” rating on the stock. Finally, BTIG Research reduced their price objective on Zoetis from $200.00 to $160.00 and set a “buy” rating for the company in a research note on Wednesday, November 12th. Six equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $178.89.

Zoetis Trading Down 0.1%

Zoetis stock opened at $127.78 on Thursday. Zoetis Inc. has a 12 month low of $115.25 and a 12 month high of $181.85. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The stock has a market cap of $56.31 billion, a P/E ratio of 21.99, a P/E/G ratio of 2.31 and a beta of 0.90. The company’s fifty day simple moving average is $136.51 and its 200-day simple moving average is $149.48.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.42 billion. During the same quarter last year, the firm earned $1.58 earnings per share. The business’s revenue for the quarter was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, sell-side analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be paid a $0.50 dividend. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 annualized dividend and a dividend yield of 1.6%. Zoetis’s payout ratio is presently 33.67%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.